Recruiting
Phase 1
Phase 2

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT04902040

Conditions

Advanced Bladder Carcinoma

Advanced Lung Non-Small Cell Carcinoma

Advanced Malignant Solid Neoplasm

Advanced Melanoma

Advanced Merkel Cell Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Atezolizumab

Avelumab

Durvalumab

Nivolumab

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information